H.P. Acthar® Gel (Repository Corticotropin Injection) Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, health economic and outcomes analyses (HEOR), reports and reviews are included and, where available, links to PubMed are provided.

Updated April 2016

Nephrology


**Neurology**


70. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology*. 2015;84(suppl 14):P2.189
Neurology – HEOR


100. Hansen R, Gold L, Schepman P, Niewoechner J, Philbin M. Economic consequences of early versus late use of adrenocorticotropic hormone therapy in infantile spasms [WCI abstract LB10]. Late-breaker abstract presented at World Congress of Inflammation Meeting; August 8-12, 2015; Boston, MA. 2015


Ophthalmology


Pulmonology


110. Baughman RP, Lower EE, Lanier O'Hare, Barney JB. Acthar Gel for refractory sarcoidosis [ATS abstract A3743]. Am J Respir Crit Care Med. 2015;191(suppl):A3743-A3743


Pulmonology – HEOR


124. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol*. 2015;194(suppl 1):139.4-139.4


132. Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and
structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. Ann Rheum Dis. 2015;74(suppl 2):1066-1067


134. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. Ann Rheum Dis. 2015;74(suppl 2):1066-1066


144. Pegram SB. The efficacy and tolerability of H.P. Acthar® Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus [EULAR abstract AB0531]. Ann Rheum Dis. 2015;74(suppl 2):1077-1078


149. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. Arch Dis Child. 1971;46(249):584-593. Link

Rheumatology – HEOR


Other


185. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone (ACTH) gel [ASN abstract SA-PO381]. *J Am Soc Nephrol*. 2012;23(suppl):725A


188. Kongelbeck SR. Discharge planning for the child with infantile spasms. *J Neurosci Nurs*. 1990;No. 4:238-244. Link


201. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotropic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. Ann Rheum Dis. 2013;72(suppl 3):904